Alpha 2.0
Login Register
» Articles » PMID: 35266185

Outcomes of Allogeneic Transplantation After Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia

Overview
Journal Am J Hematol
Specialty Hematology
Date 2022 Mar 10
PMID 35266185
Authors
Vanessa E Kennedy
Gavin Hui
Tali Azenkot
Daria Gaut
Matthew J Wieduwilt
Caspian Oliai
Brian A Jonas
Varun Mittal
Aaron C Logan
Lori S Muffly
Gabriel N Mannis
Affiliations
Soon will be listed here.
Citing Articles

Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics.

Korell F, Olson M, Salas-Benito D, Leick M, Larson R, Bouffard A Sci Transl Med. 2024; 16(750):eadk7640.

PMID: 38838132 PMC: 11737343. DOI: 10.1126/scitranslmed.adk7640.

The approach of HMA plus VEN with or without BMT for all patients with AML.

Male H, Lin T Hematology Am Soc Hematol Educ Program. 2023; 2023(1):186-191.

PMID: 38066860 PMC: 10727071. DOI: 10.1182/hematology.2023000428.

Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes.

Jiang J, Wang Y, Liu D, Wang X, Zhu Y, Tong J Immunotargets Ther. 2023; 12:135-147.

PMID: 38026089 PMC: 10680489. DOI: 10.2147/ITT.S429402.

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia.

Bang S, Park S, Kwag D, Lee J, Min G, Park S Cancers (Basel). 2023; 15(6).

PMID: 36980551 PMC: 10046472. DOI: 10.3390/cancers15061666.

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.

Kwag D, Cho B, Bang S, Lee J, Min G, Park S Blood Cancer J. 2022; 12(12):169.

PMID: 36529771 PMC: 9760636. DOI: 10.1038/s41408-022-00770-x.